bluuebunny/crossref_metadata_2025_split huggingface dataset:
Comparative oral monotherapy of psilocybin, lysergic acid diethylamide, 3,4-methylenedioxymethamphetamine, ayahuasca, and escitalopram for depressive symptoms: systematic review and Bayesian network meta-analysis
Authors: Hsu Tien-Wei , Tsai Chia-Kuang , Kao Yu-Chen , Thompson Trevor , Carvalho Andre F , Yang Fu-Chi , Tseng Ping-Tao , Hsu Chih-Wei , Yu Chia-Ling , Tu Yu-Kang , Liang Chih-Sung 
Published: August 2024

Abstract

Objective
To evaluate the comparative effectiveness and acceptability of oral monotherapy using psychedelics and escitalopram in patients with depressive symptoms, considering the potential for overestimated effectiveness due to unsuccessful blinding.

Design
Systematic review and Bayesian network meta-analysis.

Data sources
Medline, Cochrane Central Register of Controlled Trials, Embase, PsycINFO, ClinicalTrial.gov, and World Health Organization’s International Clinical Trials Registry Platform from database inception to 12 October 2023.

Eligibility criteria for selecting studies
Randomised controlled trials on psychedelics or escitalopram in adults with depressive symptoms. Eligible randomised controlled trials of psychedelics (3,4-methylenedioxymethamphetamine (known as MDMA), lysergic acid diethylamide (known as LSD), psilocybin, or ayahuasca) required oral monotherapy with no concomitant use of antidepressants.

Data extraction and synthesis
The primary outcome was change in depression, measured by the 17-item Hamilton depression rating scale. The secondary outcomes were all cause discontinuation and severe adverse events. Severe adverse events were those resulting in any of a list of negative health outcomes including, death, admission to hospital, significant or persistent incapacity, congenital birth defect or abnormality, and suicide attempt. Data were pooled using a random effects model within a Bayesian framework. To avoid estimation bias, placebo responses were distinguished between psychedelic and antidepressant trials.

Results
Placebo response in psychedelic trials was lower than that in antidepression trials of escitalopram (mean difference −3.90 (95% credible interval −7.10 to −0.96)). Although most psychedelics were better than placebo in psychedelic trials, only high dose psilocybin was better than placebo in antidepression trials of escitalopram (mean difference 6.45 (3.19 to 9.41)). However, the effect size (standardised mean difference) of high dose psilocybin decreased from large (0.88) to small (0.31) when the reference arm changed from placebo response in the psychedelic trials to antidepressant trials. The relative effect of high dose psilocybin was larger than escitalopram at 10 mg (4.66 (95% credible interval 1.36 to 7.74)) and 20 mg (4.69 (1.64 to 7.54)). None of the interventions was associated with higher all cause discontinuation or severe adverse events than the placebo.

Conclusions
Of the available psychedelic treatments for depressive symptoms, patients treated with high dose psilocybin showed better responses than those treated with placebo in the antidepressant trials, but the effect size was small.

Systematic review registration
PROSPERO, CRD42023469014.
Optimising the indications for biliary stent placement during endoscopic retrograde cholangiopancreatography: a quality improvement initiative to enhance patient care and reduce healthcare resource utilisation
Authors: Alhaidari Suliman , Alzahrani Ibrahim , Alhanaee Manar , Decanini Alan , Mohamed Mahmod , Zepeda-Gomez Sergio , Mathura Pamela , Zhang Julie , Sandha Gurpal 
Published: August 2024

BackgroundA retrospective chart audit was performed to review biliary stent utilisation from January 2020 to January 2021. Non-guideline-based stent insertion was identified in 16% of patients with common bile duct (CBD) stones presenting for endoscopic retrograde cholangiopancreatography (ERCP). To improve this knowledge-practice gap, a quality improvement (QI) intervention was devised and trialled.AimTo synchronise clinical indications for biliary stent insertion in patients with CBD stones in accordance with published guidelines.MethodsUsing a QI pre–post study design, chart audits were completed and shared with the ERCP team (n=6). Indication for biliary stent insertion was compared to published guidelines assessed by two reviewers independently (kappastatistic calculated). The QI intervention included an education session and quarterly practice audits. An interrupted time series with segmented regression was completed.ResultsA total of 661 patients (337 F), mean age 59±19 years (range 12–98 years), underwent 885 ERCPs during this postintervention period. Of 661 patients, 384 (58%) were referred for CBD stones. A total of 192 biliary stents (105 plastic, 85 metal) were placed during the first ERCP (192/661, 29%), as compared with the preintervention year (223/598, 37%, p=0.2). Furthermore, 13/192 stents (7%) were placed not in accordance with published guidelines (kappa=0.53), compared with 63/223 (28%) in the preintervention year (p<0.0001). A 75% reduction in overall avoidable stent placement was achieved with a direct cost avoidance of $C97 500. For the CBD stone subgroup, there was an 88% reduction in avoidable biliary stent placement compared with the preintervention year (8/384, 2% vs 61/375, 16%, p<0.0001).ConclusionsEducation with audit and feedback supported the closing of a knowledge-to-practice gap for biliary stent insertion during ERCP, especially in patients with CBD stones. This has resulted in a notable reduction of avoidable stent placements and additional follow-up ERCPs and an overall saving of healthcare resources.
Effect of multimorbidity on depressive status in older Chinese adults: evidence from the China Health and Retirement Longitudinal Study (CHARLS)
Authors: Chao Guanqun , Zhang Lan , Zhan Zheli , Bao Yang 
Published: August 2024

ObjectiveThis study aims to further explore the relevant influencing factors of depression and explore the correlation between multimorbidity coexistence and depression to find the goals and methods of early intervention of depression in the elderly.DesignThis study adopts a cross-sectional approach.SettingThe study population of this project came from the China Health and Retirement Longitudinal Study. Depression was grouped according to the 10-item version of Centre for Epidemiological Research Depression Scale. Chronic diseases, height, weight, grip strength, education, marital status, alcohol consumption, exercise and other indicators were included in the analysis.Participants2239 adults over 60 years of age were included.ResultsThe proportion of women in the depression group was higher (p<0.001). The depression group had a lower grip strength than the control group (p<0.05). The sleep duration was shorter in the depression group (p<0.001). There were differences in education, marital status and alcohol consumption in the depression group (p<0.05). The depression group might have more types of coexisting chronic diseases (p<0.001). The depression group was more likely to have hypertension, dyslipidaemia, chronic lung diseases, heart attack, stroke, stomach disease and memory-related disease. Grip strength was connected with the risk of depression in the elderly (0.971 (95% CI 0.959 to 0.984)). Sleep (0.827 (95% CI 0.785 to 0.872) and education level (0.790 (95% CI 0.662 to 0.942) were related to the risk of depression in the elderly. Concomitant chronic diseases could affect the risk of depression in the elderly (1.455 (95% CI 1.243 to 1.703)).ConclusionThe coexistence of multiple chronic diseases and depression is very common in the elderly. The coexistence of multiple chronic diseases is more common in older women and older depressed people. With the increase in the number of chronic diseases, the risk of depression in the elderly is significantly increased.
National retrospective registry survey on the epidemiology of sarcoidosis in Finland 2002−2022
Authors: Salonen Johanna , Kaarteenaho Riitta 
Published: August 2024

BackgroundThe prevalence of sarcoidosis is known to be high in the Nordic countries. There are no recent research data on the incidence or prevalence of sarcoidosis in Finland. Our aim was to investigate the epidemiology of sarcoidosis in Finland through a retrospective registry-based study.MethodsWe made an information request to the Hilmo database on patients who had been treated in Finnish specialised care with a main diagnosis related to sarcoidosis. Data were requested for the period 1 January−31 December for the years 2002, 2012 and 2022. In addition, we examined the age and gender distribution and regional differences in these variables between the five university hospital districts covering the whole of Finland.ResultsThe incidence of sarcoidosis was 17‒19/100 000/year throughout the follow-up period. The prevalence of sarcoidosis in the ≥18-year-old population had risen from 85/100 000 in 2002–106/100 000 in 2022. There were considerable differences between university hospital districts: The highest prevalence rate was 170/100 000 in the Tampere University Hospital district in 2022, which was twice as high as in the Helsinki University Hospital district (84/100 000). The proportion of pulmonary sarcoidosis in all sarcoidosis cases decreased from 62% to 45% while the proportion of multiorgan sarcoidosis (D86.8) increased from 11% to 34%. The incidence of sarcoidosis was 15/100 000 and the prevalence was 82/100 000 in the age groups of ≥60 years in 2002. In 2022, the incidence in this same age group had risen to 20/100 000 and the prevalence to 109/100 000. In the ≥60-year-old population, the proportion of D86.8 increased from 11% to 35%.ConclusionsSarcoidosis was a more common disease in Finland than in previous studies. Multiorgan sarcoidosis among the elderly has increased over the past 20 years. This might be explained by changes in environmental factors associated with sarcoidosis. Significant regional differences in prevalence might be partly explained by familial clustering.
Changing patterns of cigarette and ENDS transitions in the USA: a multistate transition analysis of adults in the PATH Study in 2017–2019 vs 2019–2021
Authors: Brouwer Andrew F , Jeon Jihyoun , Jimenez-Mendoza Evelyn , Land Stephanie R , Holford Theodore R , Friedman Abigail S , Tam Jamie , Mistry Ritesh , Levy David T , Meza Rafael 
Published: August 2024

IntroductionThe use of cigarettes and electronic nicotine delivery system (ENDS) has likely changed since 2019 with the rise of pods and disposables, the lung injuries outbreak, flavour bans, Tobacco 21 and the COVID-19 pandemic.MethodsUsing the Population Assessment of Tobacco and Health Study, we applied a multistate transition model to 28 061 adults in waves 4–5 (2017–2019) and 24 584 adults in waves 5–6 (2019–2021), estimating transition rates for initiation, cessation and switching products for each period overall and by age group.ResultsCigarette initiation among adults who never used either product decreased from 2017–2019 to 2019–2021, but ENDS initiation did not significantly change. The persistence of ENDS-only use remained high (75%–80% after 1 year). Cigarette-only use transitions remained similar (88% remaining, 7% to non-current use and 5% to dual or ENDS-only use). In contrast, dual use to ENDS-only transitions increased from 9.5% (95% CI 7.3% to 11.7%) to 20.0% (95% CI 17.4% to 22.6%) per year, decreasing the persistence of dual use. The dual to cigarette-only use transition remained at about 25%. These changes were qualitatively similar across adult age groups, though adults ages 18–24 years exhibited the highest probability of switching from cigarette-only use to dual use and from dual use to ENDS-only use.ConclusionsThe persistence of ENDS use among adults remained high in 2019–2021, but a larger fraction of dual users transitioned to ENDS-only use compared with 2017–2019. Because the fraction of cigarette-only users switching to dual use remained low, especially among older adults, the public health implications of this change are minimal.
Gravitational radiation in generalized Brans–Dicke theory: compact binary systems
Authors: Mahmoudi S. , Hendi S. H. 
Published: August 2024

AbstractThis paper investigates the generation and properties of gravitational radiation within the framework of generalized Brans–Dicke (GBD) theory, with a specific emphasis on its manifestation in compact binary systems. The study begins by examining the weak field equations in GBD theory, laying the foundation for subsequent analyses. Solutions to the linearized field equations for point particles are then presented, providing insights into the behavior of gravitational fields in the context of GBD theory. The equation of motion of point mass is explored, shedding light on the dynamics of compact binary systems within the GBD framework. The primary focus of this study lies in the comprehensive exploration of gravitational radiation generated by compact binaries. The energy momentum tensor and the associated gravitational wave (GW) radiation power in GBD theory are investigated, elucidating the relationship between these fundamental concepts. Furthermore, detailed calculations are provided for the GW radiation power originating from both tensor fields and scalar fields. Based on our calculations, both scalar fields contribute to GW radiation by producing dipole radiation. We also study the period derivative of compact binaries in this theory. By comparing with the observational data of the orbital period derivative of the quasicircular white dwarf-neutron star binary PSR J1012+5307, we put bounds on the two parameters of the theory: the Brans–Dicke coupling parameter $$\omega _{0}$$

ω
0

and the mass of geometrical scalar field $$m_f$$

m
f

, resulting in a lower bound $$\omega _{0}>6.09723\times 10^6$$

ω
0

>
6.09723
×

10
6

for a massless BD scalar field and the geometrical field whose mass is smaller than $$10^{-29} \text { GeV}$$

10

-
29

GeV

. The obtained bound on $$\omega _0$$

ω
0

is two orders of magnitude stricter than those derived from solar system data. Finally, we find the phase shift that GWs experience in the frequency domain during their propagation. These calculations offer a quantitative understanding of the contributions from different components within the GBD theory, facilitating a deeper comprehension of the overall behavior and characteristics of gravitational radiation.
Preclinical Characterization of ARX517, a Site-Specific Stable PSMA-Targeted Antibody–Drug Conjugate for the Treatment of Metastatic Castration-Resistant Prostate Cancer
Authors: Skidmore Lillian K. , Mills David , Kim Ji Young , Knudsen Nick A. , Nelson Jay D. , Pal Manoj , Wang Jianing , GC Kedar , Gray Michael J. , Barkho Wisam , Nagaraja Shastri Prathap , Ramprasad Mysore P. , Tian Feng , O’Connor Daniel , Buechler Ying J. , Zhang Shawn Shao-Hui 
Published: August 2024

Abstract
Metastatic castration-resistant prostate cancer (mCRPC) is an advanced disease in which patients ultimately fail standard-of-care androgen deprivation therapies and exhibit poor survival rates. The prostate-specific membrane antigen (PSMA) has been validated as an mCRPC tumor antigen with overexpression in tumors and low expression in healthy tissues. Using our proprietary technology for incorporating synthetic amino acids into proteins at selected sites, we have developed ARX517, an antibody–drug conjugate composed of a humanized anti-PSMA antibody site-specifically conjugated to a tubulin inhibitor at a drug-to-antibody ratio of 2. After binding PSMA, ARX517 is internalized and catabolized, leading to cytotoxic payload delivery and apoptosis. To minimize premature payload release and maximize delivery to tumor cells, ARX517 employs a noncleavable polyethylene glycol linker and stable oxime conjugation enabled via synthetic amino acid protein incorporation to ensure its overall stability. In vitro studies demonstrate that ARX517 selectively induces cytotoxicity of PSMA-expressing tumor cell lines. ARX517 exhibited a long terminal half-life and high serum exposure in mice and dose-dependent antitumor activity in both enzalutamide-sensitive and -resistant cell line–derived xenograft and patient-derived xenograft models of prostate cancer. Repeat-dose toxicokinetic studies in nonhuman primates demonstrated that ARX517 was tolerated at exposures well above therapeutic exposures in mouse pharmacology studies, indicating a wide therapeutic index. In summary, ARX517 inhibited tumor growth in diverse mCRPC models, demonstrated a tolerable safety profile in monkeys, and had a wide therapeutic index based on preclinical exposure data. Based on the encouraging preclinical data, ARX517 is currently being evaluated in a phase I clinical trial (NCT04662580).
Viewing Native American Cervical Cancer Disparities through the Lens of the Vaginal Microbiome: A Pilot Study
Authors: Łaniewski Paweł , Joe Tawnjerae R. , Jimenez Nicole R. , Eddie Tristen L. , Bordeaux Skyler J. , Quiroz Verity , Peace Donna J. , Cui Haiyan , Roe Denise J. , Caporaso J. Gregory , Lee Naomi R. , Herbst-Kralovetz Melissa M. 
Published: August 2024

Abstract
Vaginal dysbiosis is implicated in persistent human papillomavirus (HPV) infection and cervical cancer. Yet, there is a paucity of data on the vaginal microbiome in Native American communities. Here, we aimed to elucidate the relationships between microbiome, HPV, sociodemographic, and behavioral risk factors to better understand an increased cervical cancer risk in Native American women. In this pilot study, we recruited 31 participants (16 Native American and 15 non-Native women) in Northern Arizona and examined vaginal microbiota composition, HPV status, and immune mediators. We also assessed individuals’ sociodemographic information and physical, mental, sexual, and reproductive health. Overall, microbiota profiles were dominated by common Lactobacillus species (associated with vaginal health) or a mixture of bacterial vaginosis–associated bacteria. Only 44% of Native women exhibited Lactobacillus dominance, compared with 58% of non-Native women. Women with vaginal dysbiosis also had elevated vaginal pH and were more frequently infected with high-risk HPV. Furthermore, we observed associations of multiple people in a household, lower level of education, and high parity with vaginal dysbiosis and abundance of specific bacterial species. Finally, women with dysbiotic microbiota presented with elevated vaginal levels of proinflammatory cytokines. Altogether, these findings indicate an interplay between HPV, vaginal microbiota, and host defense, which may play a role in the cervical cancer disparity among Native American women. Future longitudinal studies are needed to determine the mechanistic role of vaginal microbiota in HPV persistence in the context of social determinants of health toward the long-term goal of reducing health disparities between non-Hispanic White and Native American populations.
Prevention Relevance: Cervical cancer disproportionally affects Native American women. Sociodemographic and behavioral factors might contribute to this disparity via alteration of vaginal microbiota. Here, we show the association between these factors and vaginal dysbiosis and immune activation, which can be implicated in high-risk HPV infection among Native American and other racial/ethnic populations.
The Proteogenomics of Prostate Cancer Radioresistance
Authors: Haas Roni , Frame Gavin , Khan Shahbaz , Neilsen Beth K. , Hong Boon Hao , Yeo Celestia P.X. , Yamaguchi Takafumi N. , Ong Enya H.W. , Zhao Wenyan , Carlin Benjamin , Yeo Eugenia L.L. , Tan Kah Min , Bugh Yuan Zhe , Zhu Chenghao , Hugh-White Rupert , Livingstone Julie , Poon Dennis J.J. , Chu Pek Lim , Patel Yash , Tao Shu , Ignatchenko Vladimir , Kurganovs Natalie J. , Higgins Geoff S. , Downes Michelle R. , Loblaw Andrew , Vesprini Danny , Kishan Amar U. , Chua Melvin L.K. , Kislinger Thomas , Boutros Paul C. , Liu Stanley K. 
Published: August 2024

AbstractProstate cancer is frequently treated with radiotherapy. Unfortunately, aggressive radioresistant relapses can arise, and the molecular underpinnings of radioresistance are unknown. Modern clinical radiotherapy is evolving to deliver higher doses of radiation in fewer fractions (hypofractionation). We therefore analyzed genomic, transcriptomic, and proteomic data to characterize prostate cancer radioresistance in cells treated with both conventionally fractionated and hypofractionated radiotherapy. Independent of fractionation schedule, resistance to radiotherapy involved massive genomic instability and abrogation of DNA mismatch repair. Specific prostate cancer driver genes were modulated at the RNA and protein levels, with distinct protein subcellular responses to radiotherapy. Conventional fractionation led to a far more aggressive biomolecular response than hypofractionation. Testing preclinical candidates identified in cell lines, we revealed POLQ (DNA Polymerase Theta) as a radiosensitizer. POLQ-modulated radioresistance in model systems and was predictive of it in large patient cohorts. The molecular response to radiation is highly multimodal and sheds light on prostate cancer lethality.Significance:Radiation is standard of care in prostate cancer. Yet, we have little understanding of its failure. We demonstrate a new paradigm that radioresistance is fractionation specific and identified POLQ as a radioresistance modulator.
Comparison of Physically Based and Empirical Modeling of Nighttime Spatial Temperature Variability during a Heatwave in and around a City
Authors: Saranko Olli , Suomi Juuso , Partanen Antti-Ilari , Fortelius Carl , Gonzales-Inca Carlos , Käyhkö Jukka 
Published: August 2024

Abstract
The numerical weather prediction model HARMONIE-AROME and a multiple linear regression model (referred to in this article as the TURCLIM model after the local climate observation network) were used to model surface air temperature for 25–31 July 2018 in the City of Turku, Finland, to study their performance in urban areas and surrounding rural areas. The 0200 LT (local standard time) temperatures modeled by the HARMONIE-AROME and TURCLIM models were compared to each other and against the observed temperatures to find the model best suited for modeling the urban heat island effect and other spatial temperature variabilities during heatwaves. Observed temperatures were collected from 74 sites, representing both rural and urban environments. Both models were able to reproduce the spatial nighttime temperature variation. However, HARMONIE-AROME modeled temperatures were systematically warmer than the observed temperatures in stable conditions. Spatial differences between the models were mostly related to the physiographic characteristics: for the urban areas, HARMONIE-AROME modeled on average 1.4°C higher temperatures than the TURCLIM model, while for other land-cover types, the average difference was 0.51°C at maximum. The TURCLIM model performed well when the explanatory variables were able to incorporate enough information on the surrounding physiography. Respectively, systematic cold or warm bias occurred in the areas in which the thermophysically relevant physiography was lacking or was only partly captured by the model.

Significance Statement
As more and more people are living in an urban environment, the demand for accurate urban climate modeling is growing. This study aims to understand the differences between the numerical weather prediction and multiple linear regression modeling and their limitations in modeling surface air temperature in subkilometer scale. The case study shows that models are capable of predicting the spatial variation of 0200 LT nighttime temperature during a heatwave in a high-latitude coastal city. Both models are therefore valuable assets for city planners who need accurate information about the impacts of the physiography on the urban climate. The results indicate that to improve the performance of the models, more accurate physiographic description and higher spatial resolution of the models are needed.